ClinicalTrials.gg
CompletedNCT00154167Updated Sep 14, 2005

Safety and Efficacy Study of NV-101 in Dental Patients

A Phase 2 interventional study of NV-101 (phentolamine mesylate solution) in Soft Tissue Anesthesia (Numbness), sponsored by Novalar Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 10 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2005-09-14.

Sponsored by Novalar Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
122
Allocation
Randomized
Ages
10 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study was:

  • to determine if NV-101 accelerates recovery from numbness compared to placebo
  • to evaluate safety of NV-101
Read the detailed description

This was a randomized, double-blind, placebo-controlled, multi-center study. One hundred twenty-two patients aged 10-58 requiring treatment with one of four routine dental procedures were enrolled. The investigators were licensed dentists in private practice. Each patient received one or more conventional injections of either articaine with epinephrine, lidocaine with epinephrine, prilocaine with epinephrine, or mepivacaine with levonordefrin. Local anesthetics were injected into no more than 2 sites. Injections of local anesthetic placed within 4mm of each other constituted the same site. The injection(s) of study drug were made at or near the completion of the dental procedure and were required to be not earlier than 20 minutes after, and not later than 70 minutes after, the most recent injection of local anesthetic. Patients received an injection of study drug (1.8 mL) in each site at which local anesthetic had been injected (i.e. no more than 2 sites).

Patients self-evaluated the return of normal sensation in the lip, tongue, nose, and chin by palpations at 5-minute intervals beginning 1 minute before the study drug injection and continuing for a minimum of 3 hours and until they achieved the return of normal sensation in lip, tongue, nose, and chin.

Safety was assessed by the use of a Holter monitor, vital signs, pain ratings, and physical examinations including oral cavity examinations.

02

Conditions studied

  • Soft Tissue Anesthesia (Numbness)

Browse trials for

03

In context

Hypesthesia

47 studies on the registry are indexed under Hypesthesia; 12 are open to participants now.

This study's enrollment of 122 is above the median of 50 across 43 interventional studies indexed under Hypesthesia.

Browse Hypesthesia studies →

Lead sponsor

Novalar Pharmaceuticals, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Between 10-65 years of age
  • Body weight between 35 to 110 kg
  • Healthy as determined by the Investigator based on medical history, physical examination, and 12 Lead
  • Clinical laboratory tests within the reference ranges or within clinically acceptable limits according to the Investigator
  • Normal lip, nose, chin, and tongue sensations
  • Women of must have agreed to use barrier for the duration of the study (Women of childbearing potential included all women except for those who are premenstrual, whose menstrual periods have not occured for greater than or equal to one year after menopause, who are surgically sterilized, or who have had a hysterectomy)
  • Can understand and sign the document, can communicate with the investigator, and can understand and comply with the requirements of the protocol

Exclusion criteria

Exclusion Criteria:

  • history or presence of respiratory, gastrointestinal, renal, hepatic, hematological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, or connective tissue disease or disorder
  • Clinically relevant surgical history
  • History of alcoholism and/or drug abuse within the past 5 years
  • Significant infection or known inflammatory process including viral infections
  • Required prophylactic antibiotics for SBE (infectious endocarditis)
  • Had acute gastrointestinal symptoms at screening and/or baseline
  • Allergies to any of the following: lidocaine/epinephrine, articaine/epinephrine, prilocaine/epinephrine, bisulfites or metasulfites, or phentolamine
  • Had used any drug and/or participated in any clinical trial within 30 days of baseline
  • Used pain relievers 24 hours prior to anesthetic administration
  • Required the use of nitrous oxide or sedatives to perform the scheduled, eligible dental procedure
  • Pregnancy, attempting to conceive,or lactating
  • Used decongestants or other drugs with vasoactive moieties within 24 hours prior to anesthetic administration
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Double
Enrollment
122 participants
06

Study locations

1 site
  • Northwest Kinetics
    Tacoma, Washington 98403, United States
07

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2003 and a completion of Jun 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2005
First posted
Sep 12, 2005
Start
Feb 2003
Completion
Jun 2003
Last update
Sep 14, 2005
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Sep 14, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00154167
Lead sponsor
Novalar Pharmaceuticals, Inc.
First posted
Sep 12, 2005
Start date
Feb 2003
Completion
Jun 2003
Last update
Sep 14, 2005

Study contacts

Royce Morrison, MD
principal investigator · Northwest Kinetics
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2005. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Phentolamine

Start the discussion